靶向T-ALL白血病起始细胞中的NOTCH1-MYC-CD44轴
该研究探讨BRD4在转录调控CD44中的作用,并使用PROTAC药物ARV-825降解BRD4,在Notch1突变患者来源异种移植和ΔPTEN遗传模型中发现可延长小鼠生存、减少白血病起始细胞并下调NOTCH1-MYC-CD44轴,二次移植证实白血病起始细胞被清除。
要点
- BRD4参与调控CD44转录,靶向BRD4可拆解NOTCH1-MYC-CD44轴。
- ARV-825降解BRD4延长Notch1突变PDX和ΔPTEN模型小鼠生存。
- ARV-825处理减少CD34+CD7+CD19-白血病起始细胞并下调相关通路。
核心结论
- 降解BRD4是有前景的靶向白血病起始细胞的T-ALL治疗策略。
研究设计与样本
- 研究使用Notch1突变患者来源异种移植模型和ΔPTEN遗传模型进行体内实验。
- 采用单细胞蛋白质组学分析PDX模型,并进行二次移植功能验证。
主要发现
- ARV-825处理延长Notch1突变PDX和ΔPTEN模型小鼠的生存。
- 单细胞蛋白质组学显示CD34+CD7+CD19-白血病起始细胞数量减少,NOTCH1-MYC-CD44轴下调,并涉及细胞周期、凋亡和PI3K/Akt通路。
- 二次移植证实经ARV-825处理的T-ALL小鼠白血病发生延迟且生存延长,功能上确认白血病起始细胞被清除。
关键数值与推荐
- 原文未报告具体数值。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The NOTCH1-MYC-CD44 axis integrates cell-intrinsic and extrinsic signaling to ensure the persistence of leukemia-initiating cells (LICs) in T-cell acute lymphoblastic leukemia (T-ALL) but a common pathway to target this circuit is poorly defined. Bromodomain-containing protein 4 (BRD4) is implicated to have a role in the transcriptional regulation of oncogenes MYC and targets downstream of NOTCH1, and here we demonstrate its role in transcriptional regulation of CD44. Hence, targeting BRD4 will dismantle the NOTCH1-MYC-CD44 axis. As a proof of concept, degrading BRD4 with proteolysis targeting chimera (PROTAC) ARV-825, prolonged the survival of mice in Notch1 mutated patient-derived xenograft (PDX) and genetic models (ΔPTEN) of T-ALL. Single-cell proteomics analysis from the PDX model, demonstrated quantitative reduction of LICs (CD34+ CD7+ CD19-) and downregulation of the NOTCH1-MYC-CD44 axis, along with cell cycle, apoptosis and PI3K/Akt pathways. Moreover, secondary transplantation from PDX and ΔPTEN models of T-ALL, confirmed delayed leukemia development and extended survival of mice engrafted with T-ALL from ARV-825 treated mice, providing functional confirmation of depletion of LICs. Hence, BRD4 degradation is a promising LIC-targeting therapy for T-ALL.
引用
- Piya S, Yang Y, Bhattacharya S, et al. Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia. 2022. PMID: 35173274. doi:10.1038/s41375-022-01516-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。